AlphAIalphai — Financial news for AI agents
yahoo.comAUG 113 min read$HIMS

Hims & Hers stock trims losses following quarterly results

Hims & Hers Health (HIMS) shares fell about 3% before narrowing losses after its Q2 results. The company reported a per-share loss of $0.37 versus a $0.17 profit a year earlier, with gross margin at 64% from 76%. Results included an $81 million one-time cost tied to Eucalyptus acquisition, restructuring, and FTC-related legal reserves. The stock is down over 4% YTD.

Original reporting
yahoo.com
Published Aug 11, 2026, 4:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 4:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Hims & Hers stock trims losses following quarterly results — source image
Source · yahoo.com
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The earnings release adds quantified deterioration (loss per share, lower gross margin) and specifies one-time costs tied to acquisition, restructuring, and FTC litigation reserves, reinforcing uncertainty around near-term profitability.

02

Market read

Traders get a same-day earnings catalyst with concrete margin and cost details plus an active FTC lawsuit backdrop, which can drive volatility and risk repricing.

03

What to watch

Investors may be underweighting the potential for gross margin recovery if restructuring and acquisition-related costs fade, and the degree to which the FTC allegations are ultimately resolved.

Relevance 7/10Novelty 6/10Timing: post-earnings, same-day volatility after Q2 results

Background

Hims & Hers has faced regulatory and legal risks tied to compounded GLP-1 weight-loss drug manufacturing, and is shifting away from copycat meds toward pharma partnerships.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

Hims & Hers reported Q2 results with a $0.37 loss per share, 64% gross margin, and $81M one-time costs tied to Eucalyptus acquisition and FTC-related litigation reserves.

Expected impact

Likely choppy trading with downside risk until investors get clarity on margin normalization and the FTC lawsuit impact.

Evidence & confidence

The article ties the earnings volatility directly to quantified financial deterioration (loss per share, gross margin down from 76% to 64%) and specific legal/restructuring costs, which typically pressure multiples and increase uncertainty premium.

Market effects

Sector

Highlights heightened regulatory and legal overhang for telehealth and compounded GLP-1 related business models, which can pressure peer sentiment.

Regional

None explicitly stated.

Global

None explicitly stated.

Counterpoint

What could challenge this read

The stock’s loss trimming after the quarterly results suggests the market may be looking through one-time items and focusing on the weight-loss strategy pivot and pharma partnerships.

Key entities

  • company
    Hims & Hers Health

    Telehealth company reporting Q2 results and facing FTC litigation related to health data and subscription cancellations.

  • regulator
    Federal Trade Commission

    Filed a lawsuit alleging Hims & Hers shared private health data with advertisers and made subscription cancellations difficult.

  • company
    Eucalyptus

    Australian-based digital health company whose acquisition is linked to one-time costs in the quarter.

  • company
    Meta

    Named as an alleged advertiser recipient of private health data in the FTC lawsuit.

  • company
    Snap

    Named as an alleged advertiser recipient of private health data in the FTC lawsuit.

Read at source← All news

Related articles

AUG 11
$HIMSMedAI 8/10

Hims & Hers Q2 revenue beat offset by wider-than-expected loss

Hims & Hers Health reported Q2 revenue of $753.2 million, up 38% year over year and above analysts’ ~$699 million estimate. The company posted a wider-than-expected loss of $0.37 per share, citing restructuring charges tied to its branded GLP-1 shift. Subscribers rose 19% to nearly 2.9 million. It raised FY2026 revenue guidance to $3.1-$3.3 billion.

yahoo.com4 min
AUG 11
$HIMSMedAI 8/10

HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook

Hims & Hers Health (HIMS) reported Q2 CY2026 revenue of $753.2 million, up 38.2% year over year, and said next-quarter revenue guidance is $890 million at the midpoint. Non-GAAP loss was $0.09 per share. Management attributed results to AI-led engagement, specialty expansion, and the June Eucalyptus acquisition, while citing higher operating expenses and litigation costs.

financialcontent.com6 min
AUG 11
$INTCMed

Stocks making the biggest moves premarket: Riot Platforms, Hims & Hers Health, Intel & more

Premarket movers included Intel, Hims & Hers Health, Riot Platforms, Plug Power, First Solar, Cardinal Health, and On Holding. Intel fell after upsizing a common stock offering to $20B. Hims & Hers shares dropped after trimming full-year EBITDA guidance and reporting a Q2 net loss. Riot rose on Q2 revenue above estimates. First Solar got a Baird upgrade with a $318 target. Cardinal Health edged up on EPS beat but revenue miss. On Holding fell after mixed results and lower revenue guidance.

cnbc.com4 min
AUG 11
$RIOTHighAI 8/10

Riot, NIQ surge, On Holding tumbles premarket

U.S. stock futures were mostly flat as investors weighed geopolitical uncertainty and awaited U.S. inflation data. In premarket earnings moves, Riot Platforms rose on a $9.1B AI data center contract with Anthropic, NIQ Global Intelligence beat and raised guidance, On Holding fell on weaker sales, and Rocket Lab dropped on margin guidance.

investing.com6 min
AUG 11
$HIMSMed

Hims & Hers shares slide as costly weight-loss push squeezes margins

Hims & Hers Health shares fell about 7% premarket after Reuters reported margin concerns despite strong Q2 results. The company said revenue beat expectations and added 300,000+ subscribers, but costs rose from branded GLP-1 weight-loss expansion and international growth, turning the quarter to a loss. It raised 2026 revenue guidance but trimmed the top end of adjusted core earnings.

investing.com4 min
AUG 11
$HIMSMedAI 8/10

Hims & Hers Health Q2 Earnings Call Highlights

Hims & Hers Health reported Q2 adjusted gross margin of 64%, down about 6 points sequentially, and said margin pressure should continue in H2 as branded weight-loss and international revenue rise. The company rolled out AI for Hers weight-loss customers, citing 3x more messages and AI answering 80% of questions. Q3 revenue guidance is $880M to $900M; Q3 adj. EBITDA $75M to $95M.

yahoo.com6 min
Hims & Hers stock trims losses following quarterly results — alphai